Related Experiment Video
Updated: Sep 18, 2025

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
Published on: November 6, 2019
Restoring Brain Function in Autism: GSK3β Inhibition by 6-Bromoindirubin-3'-oxime Reverses Valproic Acid-induced
Ashish Jain1, Neha Dhir1, Praisy K Prabha1
1Experimental Pharmacology Laboratory (EPL), Neurobehavioral Research Laboratory (NBRL), Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
6-bromoindirubin-3'-oxime (6BIO) ameliorated autism spectrum disorder (ASD) symptoms in a VPA rat model by inhibiting GSK3β. This suggests 6BIO
Area of Science:
- Neuroscience
- Pharmacology
- Developmental Biology
Background:
- Autism spectrum disorder (ASD) presents challenges in social interaction, characterized by restricted interests and repetitive behaviors.
- Current FDA-approved treatments for ASD, like aripiprazole and risperidone, primarily manage comorbid symptoms and carry significant side effects.
- Valproic acid (VPA) exposure during gestation is a known risk factor for developing ASD-like behaviors in offspring.
Purpose of the Study:
- To investigate the therapeutic potential of 6-bromoindirubin-3 omino-oxime (6BIO), a GSK3β inhibitor, in a VPA-induced rat model of ASD.
- To evaluate the effects of postnatal 6BIO administration on behavioral, cognitive, and neurobiological deficits associated with VPA exposure.
Main Methods:
- VPA was administered to pregnant Wistar rats on gestational day 12.5 to induce an ASD model.
- Offspring received daily postnatal treatment with risperidone or 6BIO (15 or 30 μg/kg) until postnatal day 82.
- Behavioral tests, neurochemical analyses (Western blotting, immunohistochemistry), and gene/protein expression studies were performed.
Main Results:
- Postnatal 6BIO treatment dose-dependently improved anxiety-like behavior, social deficits, repetitive behaviors, and cognitive functions in VPA-exposed rats.
- 6BIO administration reduced VPA-induced neuronal damage in the prefrontal cortex, hippocampus, and cerebellum.
- 6BIO suppressed upregulated GSK3β phosphorylation and modulated key genes (Wnt, CHD8, SHANK3) and proteins (β-catenin, NLGN3) involved in ASD pathophysiology.
Conclusions:
- 6-bromoindirubin-3 omino-oxime (6BIO) demonstrates significant neuroprotective effects in a VPA-induced rat model of ASD.
- The therapeutic benefits of 6BIO appear to be mediated through the inhibition of GSK3β.
- 6BIO shows promise as a potential therapeutic agent for ASD, warranting further clinical investigation.
More Related Videos
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
05:40AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke
Published on: November 29, 2024